LONDON, April 28, 2021 /PRNewswire/ -- Hikma
Pharmaceuticals PLC (Hikma), the multinational pharmaceutical
company, announces it has signed an exclusive license and
distribution agreement with AFT Pharmaceuticals (AFT) for the
commercialisation of Combogesic® IV, the US trade name
of Maxigesic IV, an intravenous, opioid free post-operative pain
relief medicine.
The licensing agreement provides Hikma with exclusive rights for
the sales, marketing and distribution of Combogesic® IV
in the US. Combogesic® IV (paracetamol 1000mg +
ibuprofen 300mg solution for infusion) is a patented intravenous
formulation developed as a line extension to Maxigesic tablets, for
use post-operatively in hospitals when patients cannot take a
medicine orally. AFT expects to file Combogesic® IV for
approval with the US FDA in the coming months.
"We are pleased to enter into this partnership with AFT for
Combogesic® IV, an important alternative for the
treatment of post-operative pain," said Riad Mishlawi, President,
Hikma Injectables. "This agreement is another example of how Hikma
is continuing to expand its pipeline in growing therapeutic areas
like non-opioid pain management treatments, and highlights the
importance of partnerships in expanding our ability to offer a
broad portfolio of high-quality medicines to US patients,
physicians and hospitals."
Enquiries
Hikma Pharmaceuticals
PLC
Susan
Ringdal
EVP, Strategic
Planning and Global Affairs
|
+44 (0)20 7399 2760/
+44 7776 477050
uk-investors@hikma.uk.com
|
|
|
Steve
Weiss
David
Belian
US Communications and
Public Affairs
|
+1 732 720 2830/ +1
732 788 8279
+1 732 720 2814/+1
848 254 4875
uscommunications@hikma.com
|
|
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across
the United States (US), the
Middle East and North Africa (MENA) and Europe, and we use our unique insight and
expertise to transform cutting-edge science into innovative
solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively
and acting practically, we provide them with a broad range of
branded and non-branded generic medicines. Together, our 8,600
colleagues are helping to shape a healthier world that enriches all
our communities. We are a leading licensing partner, and through
our venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit: www.hikma.com
View original
content:http://www.prnewswire.com/news-releases/hikma-announces-exclusive-agreement-with-aft-pharmaceuticals-for-injectable-non-opioid-pain-medication-combogesic-iv-in-the-us-301279371.html
SOURCE Hikma Pharmaceuticals USA Inc.